Louis Jammayrac
Nessuna posizione attualmente
Storia della carriera di Louis Jammayrac
Precedenti posizioni note di Louis Jammayrac
Società | Posizione | Inizio | Fine |
---|---|---|---|
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Direttore/Membro del Consiglio | 20/11/2009 | 11/03/2014 |
Neorphys SAS
Neorphys SAS Pharmaceuticals: MajorHealth Technology Founded in September 2005 by Dr Roger LAHANA, CEO, and Karine LARBOURET, Director of Operations, Neorphys is a company which discovers and develops novel, proprietary analgesic drug candidates with low side effects, especially with regard to gastro-intestinal transit. This is why the most advanced drug candidate is developed for visceral pain management. Beside the co-founders, Neorphys scientists, all PhD's or equivalent, share a strong expertise in opioids and acute pain as well as in behavioral pharmacology. They have a proven track record of success in using discovery techniques such as medicinal chemistry, cell biology, toxicology and relevant animal assays. | Direttore/Membro del Consiglio | 20/11/2009 | 11/03/2014 |
Statistiche
Distribuzione geografica
Francia | 3 |
Posizioni
Director/Board Member | 2 |
Settori
Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Health Technology |
Neorphys SAS
Neorphys SAS Pharmaceuticals: MajorHealth Technology Founded in September 2005 by Dr Roger LAHANA, CEO, and Karine LARBOURET, Director of Operations, Neorphys is a company which discovers and develops novel, proprietary analgesic drug candidates with low side effects, especially with regard to gastro-intestinal transit. This is why the most advanced drug candidate is developed for visceral pain management. Beside the co-founders, Neorphys scientists, all PhD's or equivalent, share a strong expertise in opioids and acute pain as well as in behavioral pharmacology. They have a proven track record of success in using discovery techniques such as medicinal chemistry, cell biology, toxicology and relevant animal assays. | Health Technology |
- Borsa valori
- Insiders
- Louis Jammayrac
- Esperienza